These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 27494886

  • 1. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
    Alameen AA, Simioni C, Martelli AM, Zauli G, Ultimo S, McCubrey JA, Gonelli A, Marisi G, Ulivi P, Capitani S, Neri LM.
    Oncotarget; 2016 Aug 23; 7(34):55690-55703. PubMed ID: 27494886
    [Abstract] [Full Text] [Related]

  • 2. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
    Simioni C, Ultimo S, Martelli AM, Zauli G, Milani D, McCubrey JA, Capitani S, Neri LM.
    Oncotarget; 2016 Nov 29; 7(48):79842-79853. PubMed ID: 27821800
    [Abstract] [Full Text] [Related]

  • 3. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM.
    Oncotarget; 2015 Mar 30; 6(9):6597-610. PubMed ID: 25788264
    [Abstract] [Full Text] [Related]

  • 4. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK.
    Ge J, Liu Y, Li Q, Guo X, Gu L, Ma ZG, Zhu YP.
    Biomed Environ Sci; 2013 Nov 30; 26(11):902-11. PubMed ID: 24331535
    [Abstract] [Full Text] [Related]

  • 5. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.
    Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM.
    Oncotarget; 2014 Oct 30; 5(20):10034-47. PubMed ID: 25296981
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
    Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.
    Cancer Res; 2009 Apr 15; 69(8):3520-8. PubMed ID: 19351820
    [Abstract] [Full Text] [Related]

  • 13. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP, Reynolds CP, Kang MH.
    Clin Cancer Res; 2016 Feb 01; 22(3):621-32. PubMed ID: 26080839
    [Abstract] [Full Text] [Related]

  • 14. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Gazi M, Moharram SA, Marhäll A, Kazi JU.
    Cancer Lett; 2017 Apr 28; 392():9-16. PubMed ID: 28159681
    [Abstract] [Full Text] [Related]

  • 15. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
    Pereira JK, Machado-Neto JA, Lopes MR, Morini BC, Traina F, Costa FF, Saad ST, Favaro P.
    Eur J Cancer; 2015 Sep 28; 51(14):2076-85. PubMed ID: 26238016
    [Abstract] [Full Text] [Related]

  • 16. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
    Sathe A, Chalaud G, Oppolzer I, Wong KY, von Busch M, Schmid SC, Tong Z, Retz M, Gschwend JE, Schulz WA, Nawroth R.
    PLoS One; 2018 Sep 28; 13(1):e0190854. PubMed ID: 29357370
    [Abstract] [Full Text] [Related]

  • 17. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
    Tsai JP, Lee CH, Ying TH, Lin CL, Lin CL, Hsueh JT, Hsieh YH.
    Oncotarget; 2015 Oct 06; 6(30):28851-66. PubMed ID: 26311737
    [Abstract] [Full Text] [Related]

  • 18. Tanshinone IIA Affects Autophagy and Apoptosis of Glioma Cells by Inhibiting Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway.
    Ding L, Ding L, Wang S, Wang S, Wang W, Wang W, Lv P, Lv P, Zhao D, Zhao D, Chen F, Chen F, Meng T, Meng T, Dong L, Dong L, Qi L, Qi L.
    Pharmacology; 2017 Oct 06; 99(3-4):188-195. PubMed ID: 27889779
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H, Jin X, Zhang Z, Xing Y, Kong X.
    Cell Biochem Funct; 2013 Jul 06; 31(5):427-33. PubMed ID: 23086777
    [Abstract] [Full Text] [Related]

  • 20. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.
    Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM.
    Oncotarget; 2015 Jul 10; 6(19):17147-60. PubMed ID: 26003166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.